Suppr超能文献

相似文献

2
7
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p.
Transplant Cell Ther. 2025 Jan;31(1):12.e1-12.e10. doi: 10.1016/j.jtct.2024.10.011. Epub 2024 Oct 22.
8
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13.
9
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2.
10
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

引用本文的文献

2
Cytogenetic Subclone Burden: A New Biomarker Predicting Chronic Lymphocytic Leukemia Patients Outcome.
Asian Pac J Cancer Prev. 2024 Jan 1;25(1):65-72. doi: 10.31557/APJCP.2024.25.1.65.
3
Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Cochrane Database Syst Rev. 2020 Jul 31;7(7):CD012022. doi: 10.1002/14651858.CD012022.pub2.
4
[Characteristics of chronic lymphocytic leukemia in Togo].
Pan Afr Med J. 2019 Oct 11;34:84. doi: 10.11604/pamj.2019.34.84.18752. eCollection 2019.
5
[The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China (2018 edition)].
Zhonghua Xue Ye Xue Za Zhi. 2018 May 14;39(5):353-358. doi: 10.3760/cma.j.issn.0253-2727.2018.05.001.

本文引用的文献

1
Prognostic Factors for Chronic Lymphocytic Leukemia.
Curr Hematol Malig Rep. 2016 Feb;11(1):37-42. doi: 10.1007/s11899-015-0294-x.
2
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.
3
The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
Clin Cancer Res. 2015 May 1;21(9):2148-56. doi: 10.1158/1078-0432.CCR-14-2576. Epub 2015 Feb 4.
4
How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Leuk Lymphoma. 2015 Mar;56(3):587-93. doi: 10.3109/10428194.2015.1011641. Epub 2015 Feb 17.
5
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.
6
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
Blood. 2014 Apr 3;123(14):2139-47. doi: 10.1182/blood-2013-11-539726. Epub 2014 Feb 5.
7
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
N Engl J Med. 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22.
8
Differences in incidence and trends of haematological malignancies in Japan and the United States.
Br J Haematol. 2014 Feb;164(4):536-45. doi: 10.1111/bjh.12659. Epub 2013 Nov 18.
10
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验